title: Reduction by baclofen of monosynaptic EPSPs in lumbosacral motoneurones of the anaesthetized cat.
abstract: 1. Monosynaptic excitatory postsynaptic potentials (EPSPs) were elicited in lumbosacral motoneurones of pentobarbitone anaesthetized cats by stimulating group Ia muscle afferents with most of the dorsal roots severed. In some experiments Ia EPSPs were recorded together with monosynaptic EPSPs elicited by stimulating the ipsilateral ventral quadrants (VQ) of the thoracic spinal cord. Injection of (+/-) baclofen (1 mg kg-1 I.V.) caused a reduction in the peak amplitudes of both Ia and VQ EPSPs, which started immediately upon injection and progressed gradually. No recovery in EPSP amplitude was seen during the recording period, which lasted up to 60 min. 2. The Ia EPSP peak amplitude was reduced by 18-61% (mean +/- S.D., 38 +/- 14%; n = 30), while VQ EPSPs were reduced by 7-42% (23 +/- 13%; n = 5). Baclofen had a significantly larger effect on Ia EPSPs than VQ EPSPs (P less than 0.001; t test). 3. Baclofen did not cause any consistent change in the membrane potential, nor in the membrane time constant, as estimated from the exponential decay of the tail of the EPSP. There was no tendency for the reduction in peak EPSP amplitude to be related to the estimated electrical distance on the dendritic tree at which the synaptic current was injected. 4. For two I a and two VQ EPSPs, the trial-to-trial fluctuation in the peak amplitude was resolved into quantal parameters before and after baclofen was administered. The reduction in peak amplitude was in all cases accounted for by a reduction in the probability of release of neurotransmitter, with no change in quantal size. Other EPSPs either showed negligible trial-to-trial amplitude fluctuation, or could not be resolved into quantal parameters without ambiguity. 5. By comparing the variance components of the EPSP peak amplitude distribution, the hypothesis was tested that the entire action of baclofen was to reduce quantal amplitude. This was rejected for sixteen out of thirty Ia and three out of five VQ EPSPs (P less than 0.05). 6. These results support a presynaptic site of action of baclofen on the terminals of Ia afferents, by decreasing the probability of release of neurotransmitter. They also indicate a similar, although weaker, action on VQ terminals. No evidence was found for an action on the postsynaptic membrane properties or synaptic conductance.
authors.affiliation: University Laboratory of Physiology, Oxford.
authors.forename: F R
authors.initials: FR
authors.lastname: Edwards
authors.forename: P J
authors.initials: PJ
authors.lastname: Harrison
authors.forename: J J
authors.initials: JJ
authors.lastname: Jack
authors.forename: D M
authors.initials: DM
authors.lastname: Kullmann
mesh_terms: D000818:Animals; D001418:Baclofen / Q000494:pharmacology*; D002415:Cats; D008564:Membrane Potentials / Q000187:drug effects; D009046:Motor Neurons / Q000502:physiology*; D009475:Neurons, Afferent / Q000502:physiology; D013127:Spinal Nerves / Q000502:physiology; D013570:Synaptic Membranes / Q000502:physiology*; D013997:Time Factors
chemical_list: D001418:Baclofen